Claims for Patent: 9,949,997

Summary for Patent: 9,949,997

Title:	Pharmaceutical composition, methods for treating and uses thereof
Abstract:	The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
Inventor(s):	Broedl; Uli Christian (Mainz am Rhein, DE), Johansen; Odd-Erik (Hoevik, NO), Kim; Gabriel Woojai (Mainz am Rhein, DE), Mayoux; Eric Williams (Schemmerhofen, DE), Salsali; Afshin (Princeton, NJ), Soleymanlou; Nima (Maple, CA), von Eynatten; Maximilian (Mainz, DE), Woerle; Hans-Juergen (Munich, DE), Cherney; David Z. I. (Toronto, CA), Perkins; Bruce A. (Toronto, CA), Daiber; Andreas (Scheessel, DE), Muenzel; Thomas (Mainz, DE)
Assignee:	Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:	14/918,713
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,949,997
Patent Claims:	1. A method to reduce the risk of cardiovascular death in a patient with type 2 diabetes mellitus, said method comprising administering empagliflozin to the patient, wherein said patient has cardiovascular disease, wherein the risk of cardiovascular death is reduced in said patient, wherein empagliflozin is administered orally in a total daily amount of 10 mg or 25 mg. 2. The method according to claim 1, wherein empagliflozin is administered as a pharmaceutical composition comprising 10 mg or 25 mg of empagliflozin. 3. A method to reduce the risk of hospitalization for heart failure in a patient with type 2 diabetes mellitus, said method comprising administering empagliflozin to the patient, wherein said patient has cardiovascular disease, wherein the risk of hospitalization for heart failure is reduced in said patient, wherein empagliflozin is administered orally in a total daily amount of 10 mg or 25 mg. 4. The method according to claim 3, wherein empagliflozin is administered as a pharmaceutical composition comprising 10 mg or 25 mg of empagliflozin. 5. A method to reduce the risk of all-cause mortality in a patient with type 2 diabetes mellitus, said method comprising administering empagliflozin to the patient, wherein said patient has cardiovascular disease, wherein the risk of all-cause mortality is reduced in said patient, wherein empagliflozin is administered orally in a total daily amount of 10 mg or 25 mg. 6. The method according to claim 5, wherein empagliflozin is administered as a pharmaceutical composition comprising 10 mg or 25 mg of empagliflozin. 7. The method according to claim 1, wherein empagliflozin is administered orally in a total daily amount of 10 mg. 8. The method according to claim 1, wherein empagliflozin is administered orally in a total daily amount of 25 mg. 9. The method according to claim 2, wherein said pharmaceutical composition comprises 10 mg of empagliflozin. 10. The method according to claim 2, wherein said pharmaceutical composition comprises 25 mg of empagliflozin. 11. The method according to claim 3, wherein empagliflozin is administered orally in a total daily amount of 10 mg. 12. The method according to claim 3, wherein empagliflozin is administered orally in a total daily amount of 25 mg. 13. The method according to claim 4, wherein said pharmaceutical composition comprises 10 mg of empagliflozin. 14. The method according to claim 4, wherein said pharmaceutical composition comprises 25 mg of empagliflozin. 15. The method according to claim 5, wherein empagliflozin is administered orally in a total daily amount of 10 mg. 16. The method according to claim 5, wherein empagliflozin is administered orally in a total daily amount of 25 mg. 17. The method according to claim 6, wherein said pharmaceutical composition comprises 10 mg of empagliflozin. 18. The method according to claim 6, wherein said pharmaceutical composition comprises 25 mg of empagliflozin.